Safe and Super Pure 99% Rimonabant CAS 168273-06-1 for obesity Treatment
Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug that has been withdrawn from the market due to potentially serious side effects. It was approved for use in Europe and other countries, but never approved in the United States. Rimonabant is an inverse agonist for the cannabinoid receptor CB1.
Rimonabant was the first selective CB1 receptor blocker to be approved for use anywhere in the world. In Europe, it was indicated for use in conjunction with diet and exercise for patients with a body mass index (BMI) greater than 30 kg/m⊃2;, or patients with a BMI greater than 27 kg/m⊃2; with associated risk factors, such as type 2 diabetes or dyslipidaemia. In the UK, it was available beginning in July 2006. As of 2008, the drug was available in 56 countries.
Acomplia was studied to be used complementary to diet and exercise to treat obese or overweight patients who suffer from type 2 diabetes and abnormal levels of fat in the blood.
Sanofi argued that Acomplia could also prevent the risk of cardiovascular disease.
Patients with large waist circumference (102 cm in men and 88 cm in women) were said to most benefit from taking the drug.